Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.
Wilkins D, Wählby Hamrén U, Chang Y, Clegg LE, Domachowske J, Englund JA, Muller WJ, Leach A, Kelly EJ, Villafana T. Wilkins D, et al. Among authors: wahlby hamren u. Pediatrics. 2024 Nov 1;154(5):e2024067174. doi: 10.1542/peds.2024-067174. Pediatrics. 2024. PMID: 39350745 Clinical Trial.
Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.
Wilkins D, Yuan Y, Chang Y, Aksyuk AA, Núñez BS, Wählby-Hamrén U, Zhang T, Abram ME, Leach A, Villafana T, Esser MT. Wilkins D, et al. Among authors: wahlby hamren u. Nat Med. 2024 Jun;30(6):1785. doi: 10.1038/s41591-024-03006-6. Nat Med. 2024. PMID: 38649782 Free PMC article. No abstract available.
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
Domachowske JB, Chang Y, Atanasova V, Cabañas F, Furuno K, Nguyen KA, Banu I, Kubiak RJ, Leach A, Mankad VS, Shroff M, Takas T, Villafana T, Wählby Hamrén U. Domachowske JB, et al. Among authors: wahlby hamren u. J Pediatric Infect Dis Soc. 2023 Aug 31;12(8):477-480. doi: 10.1093/jpids/piad052. J Pediatric Infect Dis Soc. 2023. PMID: 37466917 Free PMC article.
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.
Wilkins D, Yuan Y, Chang Y, Aksyuk AA, Núñez BS, Wählby-Hamrén U, Zhang T, Abram ME, Leach A, Villafana T, Esser MT. Wilkins D, et al. Among authors: wahlby hamren u. Nat Med. 2023 May;29(5):1172-1179. doi: 10.1038/s41591-023-02316-5. Epub 2023 Apr 24. Nat Med. 2023. PMID: 37095249 Free PMC article.
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, Baca Cots M, Domachowske JB, Garcia-Garcia ML, Grantina I, Nguyen KA, Zar HJ, Berglind A, Cummings C, Griffin MP, Takas T, Yuan Y, Wählby Hamrén U, Leach A, Villafana T. Simões EAF, et al. Among authors: wahlby hamren u. Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9. Lancet Child Adolesc Health. 2023. PMID: 36634694 Free PMC article.
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, Garcia-Garcia ML, Grantina I, Nguyen KA, Brooks D, Chang Y, Leach A, Takas T, Yuan Y, Griffin MP, Mankad VS, Villafana T; MEDLEY Study Group. Domachowske J, et al. N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186. N Engl J Med. 2022. PMID: 35235733 Clinical Trial. No abstract available.
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Hammitt LL, et al. Among authors: wahlby hamren u. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. N Engl J Med. 2022. PMID: 35235726 Clinical Trial.
Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.
Holmberg AA, Weidolf L, Necander S, Bold P, Sidhu S, Pelay-Gimeno M, de Ligt RAF, Verheij ER, Jauhiainen A, Psallidas I, Wählby Hamrén U, Prothon S. Holmberg AA, et al. Among authors: wahlby hamren u. Drug Metab Dispos. 2022 Feb;50(2):150-157. doi: 10.1124/dmd.121.000632. Epub 2021 Dec 1. Drug Metab Dispos. 2022. PMID: 34853068
21 results